HOXB13 and prostate cancer: Focusing first on prostate cancer (3,976 cases, 29,517 non-case men), we estimated an increased frequency of HOXB13 G84E mutation carriers among men with the disease than among men with no evidence of prostate cancer in the cohort (1.87% versus 0.78% imputation-based carriers, or 1.07% versus 0.44% actual carriers adjusting for incomplete LD).